171 related articles for article (PubMed ID: 20108160)
1. Effect of calcium and magnesium on neurotoxicity and blood platinum concentrations in patients receiving mFOLFOX6 therapy: a prospective randomized study.
Ishibashi K; Okada N; Miyazaki T; Sano M; Ishida H
Int J Clin Oncol; 2010 Feb; 15(1):82-7. PubMed ID: 20108160
[TBL] [Abstract][Full Text] [Related]
2. Phase I drug-interaction study of effects of calcium and magnesium infusions on oxaliplatin pharmacokinetics and acute neurotoxicity in colorectal cancer patients.
Han CH; Khwaounjoo P; Kilfoyle DH; Hill A; McKeage MJ
BMC Cancer; 2013 Oct; 13():495. PubMed ID: 24156389
[TBL] [Abstract][Full Text] [Related]
3. Ca/Mg infusions for the prevention of oxaliplatin-related neurotoxicity in patients with colorectal cancer: a meta-analysis.
Wen F; Zhou Y; Wang W; Hu QC; Liu YT; Zhang PF; Du ZD; Dai J; Li Q
Ann Oncol; 2013 Jan; 24(1):171-8. PubMed ID: 22898039
[TBL] [Abstract][Full Text] [Related]
4. Role of calcium/ magnesium infusion in oxaliplatin-based chemotherapy for colorectal cancer patients.
Kurniali PC; Luo LG; Weitberg AB
Oncology (Williston Park); 2010 Mar; 24(3):289-92. PubMed ID: 20394142
[TBL] [Abstract][Full Text] [Related]
5. The effect of prophylactic calcium and magnesium infusions on the incidence of neurotoxicity and clinical outcome of oxaliplatin-based systemic treatment in advanced colorectal cancer patients.
Knijn N; Tol J; Koopman M; Werter MJ; Imholz AL; Valster FA; Mol L; Vincent AD; Teerenstra S; Punt CJ
Eur J Cancer; 2011 Feb; 47(3):369-74. PubMed ID: 21067912
[TBL] [Abstract][Full Text] [Related]
6. [Reduction of oxaliplatin-related neurotoxicity by calcium and magnesium infusions].
Muto O; Ando H; Ono T; Itagaki H; Kobayashi Y; Onuki M; Akashi T; Tanaka Y; Hanaoka T
Gan To Kagaku Ryoho; 2007 Apr; 34(4):579-81. PubMed ID: 17431344
[TBL] [Abstract][Full Text] [Related]
7. Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer.
Gamelin L; Boisdron-Celle M; Delva R; Guérin-Meyer V; Ifrah N; Morel A; Gamelin E
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4055-61. PubMed ID: 15217938
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of FOLFOX or CAPOX reintroduction with or without bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
Kotaka M; Iwamoto S; Satake H; Sakai D; Kudo T; Fukunaga M; Konishi K; Ide Y; Ikumoto T; Tsuji A; Sano Y; Kato T; Sugimoto N; Satoh T; Kanazawa A; Kurata T; Yamanaka T; Tomita N
Int J Clin Oncol; 2020 Aug; 25(8):1515-1522. PubMed ID: 32409917
[TBL] [Abstract][Full Text] [Related]
9. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT.
Hochster HS; Grothey A; Hart L; Rowland K; Ansari R; Alberts S; Chowhan N; Ramanathan RK; Keaton M; Hainsworth JD; Childs BH
Ann Oncol; 2014 Jun; 25(6):1172-8. PubMed ID: 24608198
[TBL] [Abstract][Full Text] [Related]
10. Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB/Alliance).
Loprinzi CL; Qin R; Dakhil SR; Fehrenbacher L; Flynn KA; Atherton P; Seisler D; Qamar R; Lewis GC; Grothey A
J Clin Oncol; 2014 Apr; 32(10):997-1005. PubMed ID: 24297951
[TBL] [Abstract][Full Text] [Related]
11. Feasibility of sequential adjuvant chemotherapy with a 3-month oxaliplatin-based regimen followed by 3 months of capecitabine in patients with stage III and high-risk stage II colorectal cancer: JSWOG-C2 study.
Tsuruta A; Yamashita K; Tanioka H; Tsuji A; Inukai M; Yamakawa T; Yamatsuji T; Yoshimitsu M; Toyota K; Yamano T; Nagasaka T; Okajima M
Drug Des Devel Ther; 2016; 10():3827-3835. PubMed ID: 27920498
[TBL] [Abstract][Full Text] [Related]
12. Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
Oki E; Emi Y; Kojima H; Higashijima J; Kato T; Miyake Y; Kon M; Ogata Y; Takahashi K; Ishida H; Saeki H; Sakaguchi Y; Yamanaka T; Kono T; Tomita N; Baba H; Shirabe K; Kakeji Y; Maehara Y
Int J Clin Oncol; 2015 Aug; 20(4):767-75. PubMed ID: 25627820
[TBL] [Abstract][Full Text] [Related]
13. Clinical management of oxaliplatin-associated neurotoxicity.
Grothey A
Clin Colorectal Cancer; 2005 Apr; 5 Suppl 1():S38-46. PubMed ID: 15871765
[TBL] [Abstract][Full Text] [Related]
14. [Assessment of the protective effect of calcium-magnesium infusion and glutathione on oxaliplatin-induced neurotoxicity].
Dong M; Xing PY; Liu P; Feng FY; Shi YK
Zhonghua Zhong Liu Za Zhi; 2010 Mar; 32(3):208-11. PubMed ID: 20450590
[TBL] [Abstract][Full Text] [Related]
15. Infusion of calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in colorectal cancer: a systematic review and meta-analysis.
Wu Z; Ouyang J; He Z; Zhang S
Eur J Cancer; 2012 Aug; 48(12):1791-8. PubMed ID: 22542974
[TBL] [Abstract][Full Text] [Related]
16. High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatin.
Kidera Y; Satoh T; Ueda S; Okamoto W; Okamoto I; Fumita S; Yonesaka K; Hayashi H; Makimura C; Okamoto K; Kiyota H; Tsurutani J; Miyazaki M; Yoshinaga M; Fujiwara K; Yamazoe Y; Moriyama K; Tsubaki M; Chiba Y; Nishida S; Nakagawa K
Int J Clin Oncol; 2011 Jun; 16(3):244-9. PubMed ID: 21243395
[TBL] [Abstract][Full Text] [Related]
17. Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.
Yamada Y; Takahari D; Matsumoto H; Baba H; Nakamura M; Yoshida K; Yoshida M; Iwamoto S; Shimada K; Komatsu Y; Sasaki Y; Satoh T; Takahashi K; Mishima H; Muro K; Watanabe M; Sakata Y; Morita S; Shimada Y; Sugihara K
Lancet Oncol; 2013 Dec; 14(13):1278-86. PubMed ID: 24225157
[TBL] [Abstract][Full Text] [Related]
18. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
19. Intravenous calcium and magnesium for oxaliplatin-induced sensory neurotoxicity in adjuvant colon cancer: NCCTG N04C7.
Grothey A; Nikcevich DA; Sloan JA; Kugler JW; Silberstein PT; Dentchev T; Wender DB; Novotny PJ; Chitaley U; Alberts SR; Loprinzi CL
J Clin Oncol; 2011 Feb; 29(4):421-7. PubMed ID: 21189381
[TBL] [Abstract][Full Text] [Related]
20. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomized phase III study (HORIZON III).
Schmoll HJ; Cunningham D; Sobrero A; Karapetis CS; Rougier P; Koski SL; Kocakova I; Bondarenko I; Bodoky G; Mainwaring P; Salazar R; Barker P; Mookerjee B; Robertson J; Van Cutsem E
J Clin Oncol; 2012 Oct; 30(29):3588-95. PubMed ID: 22965961
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
